Annals of Colorectal Research

Published by: Kowsar

Molecular Biomarkers of Colorectal Cancer: A Review of Published Articles From Iran

Bita Geramizadeh 1 , *
Author Information
1 Department of Pathology, Transplant Research Center, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Annals of Colorectal Research: October 01, 2015, 3 (3); e30100
  • Published Online: October 9, 2015
  • Article Type: Review Article
  • Received: May 19, 2015
  • Revised: July 1, 2015
  • Accepted: July 3, 2015
  • DOI: 10.17795/acr-30100

To Cite: Geramizadeh B. Molecular Biomarkers of Colorectal Cancer: A Review of Published Articles From Iran, Ann Colorectal Res. 2015 ; 3(3):e30100. doi: 10.17795/acr-30100.

Abstract
Copyright © 2015, Colorectal Research Center and Health Policy Research Center of Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
3. KRAS Mutation
4. BRAF Mutation
5. P53
6. Other Biomarkers in Colorectal Cancer
7. Conclusions
References
  • 1. Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med. 2010; 13(2): 143-6[PubMed]
  • 2. Mohammadianpanah M. Characteristics of the patients with colorectal cancer: epidemiologic study or pathology report-based study. Iran Red Crescent Med J. 2015; 17(1)[DOI][PubMed]
  • 3. Malekzadeh R, Bishehsari F, Mahdavinia M, Ansari R. Epidemiology and molecular genetics of colorectal cancer in iran: a review. Arch Iran Med. 2009; 12(2): 161-9[PubMed]
  • 4. Mehrabani D, Tabei S, Heydari S, Shamsina S, Shokrpour N, Amini M, et al. Cancer Occurrence in Fars Province, Southern Iran. Iran Red Crescent Med J. 2008; 10(4): 314-22
  • 5. Akrami SM. Genetics of hereditary nonpolyposis colorectal cancer. Arch Iran Med. 2006; 9(4): 381-9[PubMed]
  • 6. Masoompour SM, Yarmohammadi H, Rezaianzadeh A, Lankarani KB. Cancer incidence in southern Iran, 1998-2002: results of population-based cancer registry. Cancer Epidemiol. 2011; 35(5)-7[DOI][PubMed]
  • 7. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009; 361(25): 2449-60[DOI][PubMed]
  • 8. Zamanian-Azodi M, Rezaei-Tavirani M, Hasanzadeh H, Rahmati Rad S, Dalilan S. Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach. Gastroenterol Hepatol Bed Bench. 2015; 8(1): 6-18[PubMed]
  • 9. Shemirani AI, Haghighi MM, Zadeh SM, Fatemi SR, Taleghani MY, Zali N, et al. Simplified MSI marker panel for diagnosis of colorectal cancer. Asian Pac J Cancer Prev. 2011; 12(8): 2101-4[PubMed]
  • 10. Mokarram P, Rismanchi M, Alizadeh Naeeni M, Mirab Samiee S, Paryan M, Alipour A, et al. Microsatellite instability typing in serum and tissue of patients with colorectal cancer: comparing real time PCR with hybridization probe and high-performance liquid chromatography. Mol Biol Rep. 2014; 41(5): 2835-44[DOI][PubMed]
  • 11. Shahmoradi S, Bidmeshkipour A, Salamian A, Emami MH, Kazemi Z, Salehi M. Two novel mutations in hMLH1 gene in Iranian hereditary non-polyposis colorectal cancer patients. Fam Cancer. 2012; 11(1): 13-7[DOI][PubMed]
  • 12. Montazer Haghighi M, Radpour R, Aghajani K, Zali N, Molaei M, Zali MR. Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary nonpolyposis colorectal cancer. Int J Colorectal Dis. 2009; 24(8): 885-93[DOI][PubMed]
  • 13. Milanizadeh S, Khanyaghma M, Haghighi MM, Mohebbi S, Damavand B, Almasi S, et al. Molecular analysis of imperative polymorphisms of MLH1 gene in sporadic colorectal cancer. Cancer Biomark. 2013; 13(6): 427-32[DOI][PubMed]
  • 14. Molaei M, Mansoori BK, Ghiasi S, Khatami F, Attarian H, Zali M. Colorectal cancer in Iran: immunohistochemical profiles of four mismatch repair proteins. Int J Colorectal Dis. 2010; 25(1): 63-9[DOI][PubMed]
  • 15. Haghighi MM, Aghagolzadeh P, Zadeh SM, Molaei M, Zali MR, Radpour R. Telomere shortening: a biological marker of sporadic colorectal cancer with normal expression of p53 and mismatch repair proteins. Genet Test Mol Biomarkers. 2014; 18(4): 236-44[DOI][PubMed]
  • 16. Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, Sotoudeh M, et al. Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. Ann Oncol. 2006; 17 Suppl 7-6[DOI][PubMed]
  • 17. Salehi M, Amani S, Javan S, Emami MH, Salamat MR, Daloii MRN. Evaluation of MLH1 and MSH2 gene mutations in a subset of Iranian families with hereditary nonpolyposis colorectal cancer (HNPCC). J Sci Islamic Republic Iran. 2009; 20(1): 7-12
  • 18. Brim H, Mokarram P, Naghibalhossaini F, Saberi-Firoozi M, Al-Mandhari M, Al-Mawaly K, et al. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer. 2008; 7: 68[DOI][PubMed]
  • 19. Haghighi MM, Javadi GR, Parivar K, Milanizadeh S, Zali N, Fatemi SR, et al. Frequent MSI mononucleotide markers for diagnosis of hereditary nonpolyposis colorectal cancer. Asian Pac J Cancer Prev. 2010; 11(4): 1033-5[PubMed]
  • 20. Moghbeli M, Moaven O, Dadkhah E, Farzadnia M, Roshan NM, Asadzadeh-Aghdaee H, et al. High frequency of microsatellite instability in sporadic colorectal cancer patients in Iran. Genet Mol Res. 2011; 10(4): 3520-9[DOI][PubMed]
  • 21. Faghani M, Fakhrieh Asl S, Mansour-Ghanaei F, Aminian K, Tarang A, Seighalani R, et al. The Correlation between Microsatellite Instability and the Features of Sporadic Colorectal Cancer in the North Part of Iran. Gastroenterol Res Pract. 2012; 2012: 756263[DOI][PubMed]
  • 22. Brim H, Abu-Asab MS, Nouraie M, Salazar J, Deleo J, Razjouyan H, et al. An integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors. PLoS One. 2014; 9(1)[DOI][PubMed]
  • 23. Esmailnia G, Montazer-Haghighi M, Javadi G, Parivar K, Zali M. Microsatellite instability markers status in colorectal cancer. Zahedan J Res Med Sci. 2014; 16(12): 25-8
  • 24. Zeinalian M, Emami MH, Naimi A, Salehi R, Hashemzadeh-Chaleshtori M. Immunohistochemical analysis of mismatch repair proteins in Iranian colorectal cancer patients at risk for lynch syndrome. Iran J Cancer Prev. 2015; 8(1): 7-11[PubMed]
  • 25. Zeinalian M, Emami MH, Salehi R, Naimi A, Kazemi M, Hashemzadeh-Chaleshtori M. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature. J Gastrointest Cancer. 2015; 46(2): 118-25[DOI][PubMed]
  • 26. Homayouni V, Salehi M, Kazemi M. Investigating of microsatellites instability in patients with hereditary non-polyposis colorectal cancer in Isfahan. Adv Biomed Res. 2014; 3: 145[DOI][PubMed]
  • 27. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol. 2009; 21(4): 369-73[DOI][PubMed]
  • 28. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS One. 2009; 4(9)[DOI][PubMed]
  • 29. Shemirani AI, Haghighi MM, Milanizadeh S, Taleghani MY, Fatemi SR, Damavand B, et al. The role of kras mutations and MSI status in diagnosis of colorectal cancer. Gastroenterol Hepatol Bed Bench. 2011; 4(2): 70-2[DOI][PubMed]
  • 30. Naghibalhossaini F, Hosseini HM, Mokarram P, Zamani M. High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients. Pathol Oncol Res. 2011; 17(4): 819-25[DOI][PubMed]
  • 31. Sobhani S, Ghafarpoor SM, Mostakhdemin Hosini Z, Kamali F, Noormohamadi Z, Hooshmand M. Frequency of common mutation in codon 12 and 13 of KRAS in patients with colorectal cancer in Iranian population. Genetic Third Millennium. 2009; 8: 2011-8
  • 32. Omidifar N, Geramizadeh B, Mirzai M. KRAS Mutation in Colorectal cancer, a report from South of Iran. IJMS. 5(5)
  • 33. Roskoski RJ. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun. 2010; 399(3): 313-7[DOI][PubMed]
  • 34. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011; 10(3): 385-94[DOI][PubMed]
  • 35. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer. 2006; 5: 2[DOI][PubMed]
  • 36. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer. 2011; 128(9): 2075-84[DOI][PubMed]
  • 37. Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer. 2008; 8: 255[DOI][PubMed]
  • 38. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009; 58(1): 90-6[DOI][PubMed]
  • 39. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011; 104(5): 856-62[DOI][PubMed]
  • 40. Rasuck CG, Leite SM, Komatsuzaki F, Ferreira AC, Oliveira VC, Gomes KB. Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients. Mol Biol Rep. 2012; 39(3): 2553-60[DOI][PubMed]
  • 41. Jensen LH, Dysager L, Lindebjerg J, Kolvra S, Byriel L, Cruger DG. Molecular biology from bench-to-bedside - which colorectal cancer patients should be referred for genetic counselling and risk assessment. Eur J Cancer. 2010; 46(10): 1823-8[DOI][PubMed]
  • 42. Muhammad S, Jiang Z, Liu Z, Kaur K, Wang X. The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. J Gastrointest Oncol. 2013; 4(1): 72-81[DOI][PubMed]
  • 43. Katsios C, Ziogas DE, Roukos DH. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. Expert Rev Gastroenterol Hepatol. 2010; 4(5): 525-9[DOI][PubMed]
  • 44. Chaiyapan W, Duangpakdee P, Boonpipattanapong T, Kanngern S, Sangkhathat S. Somatic mutations of K-ras and BRAF in Thai colorectal cancer and their prognostic value. Asian Pac J Cancer Prev. 2013; 14(1): 329-32[PubMed]
  • 45. Luevano-Gonzalez A, Guzman AQ, Ancer Rodriguez J, Ortiz Lopez R, Rojas Martinez A, Gonzalez Guerrero JF, et al. Analysis of DNA mismatch repair proteins expression and BRAF V600E mutation in a subset of early- and late-onset colorectal carcinoma patients in Mexico. Arch Med Res. 2011; 42(6): 457-62[DOI][PubMed]
  • 46. Bond CE, Umapathy A, Buttenshaw RL, Wockner L, Leggett BA, Whitehall VL. Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers. PLoS One. 2012; 7(10)[DOI][PubMed]
  • 47. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65(14): 6063-9[DOI][PubMed]
  • 48. Ghaffarpour M, Mohammadi Pargoo E, Sobhani S, Pirmoradi S, Mostakhdemin Hosseini Z, Kamali F. PIK3CA and BRAF mutational status and association with clinicopathological features in Iranian colonrectal cancer patients. Cancer Res. 2011; 71: 3799[DOI]
  • 49. Javadi F, Geramizadeh B, Mirzai M. BRAF Gene Mutation Analysis in Colorectal Cancer in South of Iran. Ann Colorectal Res. 2014; 2(2)
  • 50. Vatandoost N, Ghanbari J, Mojaver M, Avan A, Ghayour-Mobarhan M, Nedaeinia R, et al. Early detection of colorectal cancer: from conventional methods to novel biomarkers. J Cancer Res Clin Oncol. 2015; [DOI][PubMed]
  • 51. Bidgoli SA, Azizi E, Zavarhei MD. Association between p53 expression and Bcl-2, P-glycoprotein, topoisomerase II alpha, thymidylate synthase and thymidine phosphorylase as potential therapeutic targets in colorectal cancer patients. Pak J Biol Sci. 2007; 10(19): 3350-5[PubMed]
  • 52. Ghavam-Nasiri MR, Rezaei E, Ghafarzadegan K, Seilanian-Toosi M, Malekifard H. Expression of p53 in colorectal carcinoma: correlation with clinicopathologic features. Arch Iran Med. 2007; 10(1): 38-42[PubMed]
  • 53. Doosti A, Zamani M, Ghasemi Dehkordi P, Taheri Sh , Banitalebi M, Mahmoudzadeh M. Association of the p53 codon 72 polymorphism with colorectal cancer in South West of Iran. Sci Res Essays. 2011; 6(15): 3148-52
  • 54. Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A. p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer. 2010; 47(1): 31-4[DOI][PubMed]
  • 55. Dastjerdi MN. TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan. Acta Med Iran. 2011; 49(2): 71-7[PubMed]
  • 56. Golmohammadi R, Namazi MJ, Nikbakht M, Salehi M, Derakhshan MH. Characterization and Prognostic Value of Mutations in Exons 5 and 6 of the p53 Gene in Patients with Colorectal Cancers in Central Iran. Gut Liver. 2013; 7(3): 295-302[DOI][PubMed]
  • 57. Nejad AL, Yaghoobi MM. Mutation Analysis of TP53 Tumor Suppressor Gene in Colorectal Cancer in Patients from Iran (Kerman Province). Iran J Basic Med Sci. 2012; 15(1): 683-90[PubMed]
  • 58. Hasanpour M, Galehdari H, Masjedizadeh A, Ajami N. A unique profile of adenomatous polyposis coli gene mutations in Iranian patients suffering sporadic colorectal cancer. Cell J. 2014; 16(1): 17-24[PubMed]
  • 59. Kashfi SM, Golmohammadi M, Behboudi F, Nazemalhosseini-Mojarad E, Zali MR. MUTYH the base excision repair gene family member associated with colorectal cancer polyposis. Gastroenterol Hepatol Bed Bench. 2013; 6[PubMed]
  • 60. Akbari Z, Safari-Alighiarloo N, Haghighi MM, Vahedi M, Mirtalebi H, Azimzadeh P, et al. Lack of influence of the SMAD7 gene rs2337107 polymorphism on risk of colorectal cancer in an Iranian population. Asian Pac J Cancer Prev. 2014; 15(11): 4437-41[PubMed]
  • 61. Farzanehfar M, Vossoughinia H, Jabini R, Tavassoli A, Saadatnia H, Khorashad AK, et al. Evaluation of methylation of MGMT (O(6)-methylguanine-DNA methyltransferase) gene promoter in sporadic colorectal cancer. DNA Cell Biol. 2013; 32(7): 371-7[DOI][PubMed]
  • 62. Mojtahedi Z, Erfani N, Haghshenas MR, Hosseini SV, Ghaderi A. Association of FoxP3/Scurfin Germline Polymorphism (C-2383T/rs3761549) with Colorectal Cancer. Ann Colorectal Res. 2013; 1(1): 12-6
  • 63. Mojtahedi Z, Mohmedi M, Rahimifar S, Erfani N, Hosseini SV, Ghaderi A. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. Gene. 2012; 508(2): 229-32[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments